Skip to main content
Skip to navigation
Showing 1-10 of 43
results per page
Energizing the Immune System to Eat Cancer
January 21, 2019
Immune cells called macrophages are supposed to serve and protect, but cancer has found ways to put them to sleep. Now researchers at the Abramson Cancer Center of the University of Pennsylvania say they’ve identified how to fuel macrophages with the energy needed to attack and eat cancer cells.
Penn’s Abramson Cancer Center Welcomes New Director’s Leadership Council Chair
January 15, 2019
The Abramson Cancer Center at the University of Pennsylvania announced today that Richard S. Schiffrin, Esq., has been appointed chair of the Center Director’s Leadership Council (ACCDLC), replacing outgoing chair Richard W. Vague.
Two Ways Cancer Resists Treatment Are Actually Connected, with One Activating the Other
December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting the survival of patients.
New Imaging Tools that Trace Key Breast Cancer Enzymes May Help Guide Therapies
December 06, 2018
A set of emerging diagnostic tools may help identify breast cancer patients who are most likely to benefit from therapies that target important enzymes fueling a range of subtypes, including BRCA-mutated and triple negative cancers.
Global Trial Shows CAR T Therapy Can Lead to Durable Remissions in Non-Hodgkin’s Lymphoma
November 30, 2018
In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
FDA Approves New Targeted Drug for Leukemia Tested at University of Pennsylvania
November 28, 2018
The U.S. Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene.
CAR T Studies Highlight Abramson Cancer Center Research at ASH Annual Meeting
November 26, 2018
From better-understanding how to improve response rates in multiple myeloma patients to identifying why some patients with other types of cancer are resistant in the first place, research from the Abramson Cancer Center of the University of Pennsylvania continues to pace the field in expanding knowledge of cellular therapies for cancer care.
Abramson Cancer Center Joins National Comprehensive Cancer Network
November 20, 2018
The Abramson Cancer Center (ACC) at the University of Pennsylvania announced today that it is joining the National Comprehensive Cancer Network® (NCCN®) as its 28th member institution. The ACC joins top academic cancer centers from across the United States in creating the most frequently updated cancer care guidelines worldwide.
Anti-Malaria Drugs Have Shown Promise in Treating Cancer, and Now Researchers Know Why
November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson Cancer Center of the University of Pennsylvania say they have identified that target – an enzyme called PPT1 – opening up a new pathway for potential cancer treatments.
Abramson Cancer Center Receives $10.7 Million to Study CAR T Cells in Solid Tumors
October 22, 2018
A new program project grant from the National Cancer Institute (NCI) will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor (CAR) T cell therapy at fighting solid tumors.
Showing 1-10 of 43
results per page
For Patients and the General Public:
Share This Page:
Publications & Special Projects
Media Resources and Contacts